The Great State of Pharmaceuticals & Biotechnology 2017 - Powered by PhRMA
Date and Time
Tuesday, August 1st, 2017
8:00 AM - 6:30 PM CDT
1500 Park Pl Blvd
St. Louis Park, MN 55416
MEMBERS $149 / NON-MEMBER $249 (See sponsorship info below)
Thank you to our Platinum sponsor, PhRMA.
The Great State of Pharmaceuticals & Biotechnology 2017 brings Medical Alley’s drug industry together for a day of learning, networking, and fellowship. The conference will feature exceptional industry content and the opportunity to connect with suppliers, consultants and peers to fuel the connectivity of your Medical Alley community. It’s a trade fair, a conference, an exhibition and peer networking event.
In its second year the conferences build on the over 200 people that attended the inaugural event with more networking, content, and a new slate of showcase companies.
Thank you to our Silver Sponsors
8:00 – 8:30am - Registration, Networking, and Breakfast
8:30 – 8:40am - Conference Welcome
- Shaye Mandle, President & CEO, Medical Alley Association
8:40 – 8:50am - Company Showcase 1: Rovermed
- Laura Brod, CEO, RoverMed
8:50 – 9:50am - Session 1: Incubology and Discovery Square: BioPharma Infrastructure Investments in Medical Alley
- Dan Buettner, J.D., Director, Cushman & Wakefield
- Chris Schad, Senior Strategy Consultant, Destination Medical Center
Recent investments are bolstering Medical Alley’s infrastructure for the development of biotechnology and pharmaceutical companies. This session will feature two critical investments, Incubology and Discovery Square.
Incubology is a private incubator space in Oakdale housed in the former Imation HQ labs. With ample lab, manufacturing, clean room, and office space, Incubology offers a unique set of amenities for startup to scale up of biotech, pharmaceutical, and other high-tech firms.
Discovery Square is the is a keystone to the DMC economic development strategy and represents the future of biomedical research, education and technology innovation. With construction to start later this year established and emerging biotech firms will have access to high quality space in close proximity to major research labs at the Mayo Clinic.
9:50 – 10:30am - Networking Break
10:30 – 10:40am - Company Showcase 2: Pairnomix
- Matt Fox, CEO, Pairnomix
10:40 – 11:30am - Keynote 1: Fireside Chat with Andrew Kaplan of Takeda Pharmaceuticals USA, Inc. and Shaye Mandle of the Medical Alley Association
- Andrew G. Kaplan, VP, Government & External Affairs, Takeda Pharmaceuticals USA, Inc.
11:30 – 1:00pm - Networking Lunch
1:15 – 1:25pm - Company Showcase 3: SpineThera
- Emily Meyering, Director of R&D, SpineThera
1:30 – 2:30pm - Session 2: Alliance Management: The Challenge and the Opportunity
- Ann Trampas, Professional Development Practice Lead, Phoenix Consulting
2:30 – 3:30pm - Keynote 2
- Dr. Linda Burns, Vice President and Medical Director, Medical Services Department, National Marrow Donor Program/Be The Match, will discuss the work of Be the Match BioTherapies, a new business offering that is advancing the state of cellular therapy right in our backyard.
3:30 – 3:50pm - Networking Break
3:50 – 4:50pm - Session 3: Case Studies of Non-Dilutive Financing in Emerging BioPharma Ventures
- Pat Dillon, Director, MN-SBIR, Minnesota High Tech Association
- Jeff Liter, B-MoGen Biotechnologies
- Jeff Missling, CEO, SpineThera
- Brian Lawerence, CEO & Co-Founder, Silk Technologies
Capital is always a challenge for startups. Yet a large source of non-dilutive funding available to high risk startups is rarely pursued. Federal Government sources of capital like the SBIR program can accelerate the development of a venture without giving up equity. In this session case studies will be presented of firms that sought and received non-dilutive funding. What were their challenges? What made it work?
4:50 – 6:30pm - Network Cocktail Reception
- Fang Consulting
- Lifecore Biomedical
- Pelican BioThermal
- Verum Technical
Sponsorship Opportunities (Members Only)
Platinum / Naming Sponsor - $10,000 - SOLD OUT!
Gold Sponsor - $5,000
Silver Sponsor - $2,500
Exhibitor - $750
Click here to see for sponsorship benefits and more info.
GRAB YOUR EXHIBITOR TABLE OR SPONSORSHIP TODAY!
Keynote: Dr. Linda Burns, Vice President and Medical Director, Medical Services Department, National Marrow Donor Program/Be The Match
Dr. Linda Burns is Vice President and Medical Director of the Medical Services Department at the National Marrow Donor Program/Be The Match and Senior Scientific Director of the Health Services Research Program within the Center for International Blood and Marrow Transplant Research in Minneapolis, MN. Dr. Burns received her medical degree from the University of Missouri-Columbia, followed by a residency and chief-residency in Internal Medicine and a fellowship in Hematology/Oncology at the University of Iowa. As a Professor of Medicine in the Adult Blood and Marrow Transplant Program at the University of Minnesota from 1992-2014, her clinical research interests focused on development of novel therapies for blood cancers such as leukemia and lymphoma, and the late effects of transplantation. Following completion of her year as President of the American Society of Hematology in 2014, she transitioned to her current roles at the National Marrow Donor Program where she is actively involved in Be The Match BioTherapies and prospective clinical trials utilizing novel cellular therapies.
Pat Dillon, Director, MN-SBIR, Minnesota High Tech Association
Ms. Pat Dillon is the director of MN-SBIR, a federal and state funded program to foster a more innovative Minnesota economy focused on turning new ideas and inventions into products and technologies that spur job growth and competitiveness while promoting economic development. In this position, Dillon is responsible for the strategic direction and leadership of MN-SBIR and its services to seed, startup and small businesses in Minnesota. Dillon has consulted with hundreds of businesses to support technology innovation and commercialization in science and technology sectors important to state and national economies.
Dillon is a 1999 recipient of the prestigious SBA Tibbetts Award; a national award for excellence in the SBIR/STTR Programs. Dillon is a 2001 recipient of the City Business’ 25 Most Innovative Woman Award (now the Minneapolis/St. Paul Business Journal). Dillon has served on commercialization review committees at the National Science Foundation (twice) and the United States Department of Agriculture (multiple times), and was the principal investigator of an Office of Naval Research contract for SBIR outreach in a five state region for the first-ever SWIFT Tour (SBIR/STTR Where Innovation Focuses on Technology).
Dillon is a retired United States Navy Commander with 40 years of service (active and reserve). CDR Dillon is a combat veteran having served 10 months in Kabul, Afghanistan in support of Operation Enduring Freedom/Noble Eagle. Dillon earned a MBA and BS in Business Administration from Winona State University, Winona, MN.
Matt Fox, CEO, Pairnomix
As CEO, Matthew Fox is responsible for overseeing the company’s operations, developing the growth strategy, and delivering revenue and profitability. Prior to joining Pairnomix, Matthew served as Senior Vice President of Corporate Strategy at Upsher-Smith Laboratories, Inc., leading business intelligence efforts, developing and maintaining trade and advocacy partnerships, and sourcing new opportunities to expand and grow the business. Prior to that role, Matthew spent ten years professionally investing globally in biotechnology and pharmaceutical companies and served as a Portfolio Manager at Bank am Bellevue in Zurich, Switzerland. He holds a B.A. in Neuroscience and Behavior from Wesleyan University (CT).
Keynote: Andrew Kaplan, VP, Government & External Affairs, Takeda Pharmaceuticals USA, Inc.
Andrew G. Kaplan currently serves as Vice President of Government and External Affairs for Takeda Pharmaceuticals USA. In this role Andrew is responsible Takeda’s engagement on federal and state legislative issues and managing relationships with U.S. agencies, legislatures, and governmental administrations.
Prior to joining Takeda Andrew worked at Abbvie where he was Vice-President, Federal Government Affairs and Head of the Washington, DC office. In this role, Andrew oversaw Abbvie’s entire advocacy before Congress, the White House, and other federal agencies. Prior to joining Abbvie, Andrew spent eight years at AstraZeneca, culminating with oversight of the Washington, DC office and managing issues related to entitlement reform and deficit reduction.
Prior to joining AstraZeneca in 2005, Andrew served as Deputy Finance Director for the National Republican Congressional Committee (NRCC), coordinating the fundraising and political efforts of the NRCC in the PAC and business community. Andrew first joined the NRCC in 2002, responsible for assisting congressional campaigns with their fundraising events and arranging appearances by President Bush, Vice President Cheney and the Speaker of the House, among other national leaders. During 2002 election cycle, Andrew traveled to over 30 states and raised over $10,000,000 for competitive congressional races across the country. Prior to 2002, Andrew served on a variety of other campaigns at all levels of elected office.
Andrew graduated from the University of Vermont with a Bachelor of Arts degree in Political Science, and currently lives on Capitol Hill in Washington, DC with his wife and three daughters.
Brian Lawerence, CEO & Co-Founder, Silk Technologies
Dr. Brian Lawrence is the CEO and co-founder of Silk Technologies, Ltd, and co-inventor of the company's patented silk-derived protein technology for use in the treatment of dry eye disease. Since the technology's inception the company has garnered nearly $5M in SBIR funding, and continues to actively compete for awards today. Brian is a recognized world expert in silk protein technology with over a dozen publications and several issued patents within the space. Brian completed his Ph.D. in Biomedical Engineering from Cornell University and an M.S. in Biomedical Engineering from Tufts University. Previous to graduate school Brian worked as a process engineer in the chemical manufacturing industry at AMRESCO, a division of VWR. He received his B.S.E. in Bioengineering from the University of Toledo graduating Magna Cum Laude.
Jeff Missling, CEO, SpineThera
Jeff Missling is the founder and CEO of SpineThera. He has built SpineThera as a semi-virtual company with in-house formulation development and pilot plant operations and contracted services for all supporting functions. Jeff has further established a world class team of clinical and regulatory consultants (C-level and FDA director level). Mr. Missling has an extensive background in formulation, preclinical, and clinical development of polymeric, sustained release products including biodegradable microspheres, ophthalmic implants, drug coated medical devices, and biodegradable implants. Before founding SpineThera, Jeff led the formulation development and clinical study manufacturing of a sustained release steroid implant for ocular administration that was licensed to Merck for $40M. A chemical engineer trained at the University of Wisconsin-Madison, Jeff has spent his career developing functional polymeric materials including polymeric batteries, medical devices, and sustained-release drug products.
Chris Schad, Senior Strategy Consultant, Destination Medical Center
In his current role as Senior Strategy Consultant for Mayo Clinic Planning Services, Chris provides strategic and tactical support to the Mayo Clinic Destination Medical Center development plan - specifically on Discovery Square - through analysis and project development, oversight, and implementation geared towards Discovery Square tenant occupancy by businesses in biotech, laboratory, and technology sectors.
He worked in a variety of leadership positions in clinical and research laboratories after coming to Mayo Clinic in 1986. He was a systems analyst in research operations of the Clinical Research Unit, where his responsibilities focused on business process analysis, project management, the development and refinement of clinical research practice, and integration with other Mayo systems. Mr. Schad then transitioned to providing administrative support for the Center for Individualized Medicine (CIM). There he provided operations administration support for three laboratories in the Medical Genome Center and for the Pharmacogenomics Program. Responsibilities included budget preparation and management and business plan development across a multidisciplinary portfolio. He served as primary liaison and coordinator for strategic partnerships with both academic and industry partners. He is a published author on many peer-reviewed scientific papers, including several as first author.
Mr. Schad is a graduate of the University of Wisconsin-Eau Claire and holds a Master’s in Business Administration. He is an Assistant Professor of Laboratory Medicine in the Mayo Clinic College of Medicine.
Ann Trampas, Professional Development Practice Lead, Phoenix Consulting
Ann E Trampas, CSAP, is the Professional Development Practice Lead for Phoenix Consulting and Lecturer at the University of Illinois – Chicago (UIC). As Practice Lead she works with clients developing and delivering skills mastery classes in collaborative relationship management and consulting in optimizing their strategic alliances. At UIC, she teaches classes in Channels of Distribution, Marketing and Business Strategy. She is currently the President-Emeritus of the Midwest Chapter of the Association of Strategic Alliance Professionals (ASAP) and a member of the Technical Advisory Group for the ISO standard for Collaborative Business. Previously Ann has held positions including ASAP Certification Program Director ASAP and Vice President of Global Alliances for IBM-SPSS.